Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. It is used off-label outside its FDA approval for Behçet's disease and other conditions. Infliximab is administered by intravenous infusion, typically at six- to eight-week intervals. It cannot be given by mouth because the digestive system would destroy the drug. - Source: Wikipedia
- News
- Policy
-
Commentary
- Commentary Main
- Corrections
- Editorials
- Letters
- Cheryl K. Chumley
- Kelly Sadler
- Jed Babbin
- Tom Basile
- Tim Constantine
- Joseph Curl
- Joseph R. DeTrani
- Don Feder
- Billy Hallowell
- Daniel N. Hoffman
- David Keene
- Robert Knight
- Gene Marks
- Clifford D. May
- Michael McKenna
- Stephen Moore
- Tim Murtaugh
- Peter Navarro
- Everett Piper
- Cal Thomas
- Scott Walker
- Miles Yu
- Black Voices
- Books
- Cartoons
- To the Republic
- Sports
-
Sponsored
- Corrections
- D.C. Board of Elections
- Transportation 2026
- American energy unleashed
- Infrastructure 2026
- Building the health care Americans deserve
- Revitalizing Rural America
- Unbridled Clean Energy
- Faith at Work
- Building a healthier America
- Investing in American Health
- Free Iran 2025
- Invest in Greece 2025
- Events
- Video/Podcasts
- Games
-
- Subscribe
- Sign In